317 related articles for article (PubMed ID: 21773754)
1. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.
Kim SH; Choi Y; Jeong HY; Lee K; Chae JY; Moon KC
Virchows Arch; 2011 Sep; 459(3):299-306. PubMed ID: 21773754
[TBL] [Abstract][Full Text] [Related]
2. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
3. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
4. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
5. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
6. Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods.
Lee HJ; Shin DH; Noh GY; Kim YK; Kim A; Shin N; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
Oncotarget; 2017 May; 8(19):30756-30765. PubMed ID: 28415646
[TBL] [Abstract][Full Text] [Related]
7. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
[TBL] [Abstract][Full Text] [Related]
8. Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas.
Mosquera JM; Dal Cin P; Mertz KD; Perner S; Davis IJ; Fisher DE; Rubin MA; Hirsch MS
Diagn Mol Pathol; 2011 Sep; 20(3):129-37. PubMed ID: 21817901
[TBL] [Abstract][Full Text] [Related]
9. RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.
Argani P; Zhang L; Reuter VE; Tickoo SK; Antonescu CR
Am J Surg Pathol; 2017 May; 41(5):655-662. PubMed ID: 28296677
[TBL] [Abstract][Full Text] [Related]
10. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population.
Qu Y; Gu C; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
Sci Rep; 2016 Feb; 6():21677. PubMed ID: 26880493
[TBL] [Abstract][Full Text] [Related]
12. Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma.
Zhong M; De Angelo P; Osborne L; Keane-Tarchichi M; Goldfischer M; Edelmann L; Yang Y; Linehan WM; Merino MJ; Aisner S; Hameed M
Am J Surg Pathol; 2010 Jun; 34(6):757-66. PubMed ID: 20421778
[TBL] [Abstract][Full Text] [Related]
13. The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.
Al-Maghrabi J; Mufti S; Gomaa W
Pol J Pathol; 2018; 69(4):376-383. PubMed ID: 30786687
[TBL] [Abstract][Full Text] [Related]
14. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
15. A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.
Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Fukumura Y; Nagashima Y; Argani P; Yao T
Int J Clin Exp Pathol; 2013; 6(11):2585-90. PubMed ID: 24228124
[TBL] [Abstract][Full Text] [Related]
16. A case of TFE3 translocation renal cell carcinoma with rare morphological features and literature review.
Xia T; Long H; Liao D; Wang W; Xiao X
Indian J Pathol Microbiol; 2023; 66(1):135-140. PubMed ID: 36656224
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
18. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.
He J; Chen X; Gan W; Zhu B; Fan X; Guo H; Jia R
Future Oncol; 2015; 11(24):3243-52. PubMed ID: 26169997
[TBL] [Abstract][Full Text] [Related]
19. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
[TBL] [Abstract][Full Text] [Related]
20. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]